ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total revenues for Q3 2025 reached $278.6 million, an 11% increase year-over-year.
• DAYBUE generated net sales of $101.1 million, up 11% year-over-year.
• NUPLAZID achieved record net sales of $177.5 million, representing a 12% year-over-year growth, driven by a 9% increase in volume.
• Gross-to-net adjustments: DAYBUE at 22% and NUPLAZID at 25%.
• R&D expenses rose to $87.8 million, up from $66.6 million in Q3 2024, primarily due to increased clinical trial costs.
• SG&A expenses were flat at $133.4 million.
• Cash position improved to $847 million from $762 million at the end of Q2 2025.

2. Strategic Updates and Business Highlights:

• DAYBUE's field force expansion has resulted in the highest sequential increase in referrals since its launch, with over 1,000 unique patients treated globally.
• NUPLAZID's growth is supported by strategic investments in a larger field force and direct-to-consumer campaigns.
• The company initiated a Phase II trial for ACP-204 in Lewy body dementia psychosis and a Phase III trial for trofinetide in Japan.
• Positive momentum in both DAYBUE and NUPLAZID positions ACADIA for sustained growth into 2026.

3. Forward Guidance and Outlook:

• For NUPLAZID, the revenue guidance was raised to $685 million to $695 million for the full year, up from a previous range of $665 million to $690 million.
• DAYBUE's guidance was narrowed to $385 million to $400 million, reflecting contributions from named patient supply programs.
• R&D expense guidance increased to $335 million to $345 million, while SG&A expenses are expected to be $540 million to $555 million.
• ACADIA aims to exceed $1 billion in total revenues for 2025 and is focused on building a robust pipeline for future growth.

4. Bad News, Challenges, or Points of Concern:

• The company faced a setback with the COMPASS Prader-Willi syndrome study, which did not meet expectations, potentially impacting future growth projections.
• Market penetration for DAYBUE remains relatively low, particularly among older patients, indicating a need for continued educational efforts.
• Competitive pressures are increasing in the Parkinson's market, with larger companies expanding their presence, which could affect NUPLAZID's market share.

5. Notable Q&A Insights:

• The expanded NUPLAZID sales force will target both newly activated prescribers and existing channels, with a focus on community settings.
• The company is optimistic about the potential for ACP-204 based on learnings from pimavanserin, particularly regarding exposure-response relationships.
• There is a strategic emphasis on educating healthcare providers about the importance of addressing non-motor symptoms in Parkinson's disease, which could enhance NUPLAZID's adoption.
• The company is preparing for the European launch of DAYBUE, with ongoing discussions about reimbursement strategies in key markets like Germany.

Overall, ACADIA Pharmaceuticals reported a strong quarter with positive revenue growth and strategic advancements, while also acknowledging challenges in market penetration and competitive dynamics.